Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2923996 | 1.00 | TBK1 (0.49) | TBK1LMNAIKBKEGPR119HRH3 | |
| SCHEMBL2927254 | 0.85 | LMNA (0.48) | LMNAGPR119HRH3POLB | |
| SCHEMBL2927251 | 0.85 | LMNA (0.48) | LMNAGPR119HRH3POLB | |
| SCHEMBL2927293 | 0.83 | FAAH (0.47) | TBK1LMNAGPR119HRH3POLB | |
| SCHEMBL2927290 | 0.83 | FAAH (0.47) | TBK1LMNAGPR119HRH3POLB | |
| SCHEMBL3859432 | 0.83 | HRH3 (0.51) | TBK1LMNAIKBKEGPR119HRH3 | |
| Hydrochloric Acid SCHEMBL3863815 | 0.82 | HRH3 (0.50) | TBK1LMNAIKBKEGPR119HRH3 | |
| SCHEMBL2930146 | 0.82 | KMT2A (0.46) | LMNAGPR119HRH3POLB | |
| SCHEMBL2930563 | 0.82 | LMNA (0.47) | TBK1LMNAHRH3POLB | |
| SCHEMBL2930561 | 0.82 | LMNA (0.47) | TBK1LMNAHRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | claimed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | claimed |
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | HRH3, HRH4, HCAR2 | TBK1 3399/4885LMNA 2554/4885IKBKE 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.